LA JOLLA, Calif., June 11, 2019 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs, today announced Jake
Nunn and Simos Simeonidis,
Ph.D. have been appointed to the Company's board of directors.
Concurrently with their appointments to the Board, Mr. Nunn was
appointed to serve on the Audit Committee and Dr. Simeonidis was
appointed to serve on the Corporate Governance & Nominating
Committee.
"We are pleased to add Jake and Simos to the Regulus
board. Both bring a depth of experience that we believe will
add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the
Board of Directors of Regulus.
Mr. Nunn is a venture advisor at New Enterprise Associates (NEA)
and Dr. Simeonidis is a partner with Sarissa Capital. Both
NEA and Sarissa Capital participated in the Company's previously
announced $41.8 million private
placement of equity.
Mr. Nunn is currently a venture advisor at New Enterprise
Associates, Inc., a venture capital firm, where he was a partner
from June 2006 until January 2019. Prior to joining NEA, he served as
a partner and an analyst for the MPM BioEquities Fund, a life
sciences fund at MPM Capital, L.P., a private equity firm.
Previously, he was a healthcare research analyst and portfolio
manager at Franklin Templeton Investments and an investment banker
with Alex. Brown & Sons. Mr.
Nunn currently serves on the board of directors of Dermira, a
publicly-held biopharmaceutical company focused on dermatology,
Trevena, Inc., a publicly-held biotechnology company focused on CNS
and Addex Therapeutics Ltd., a publicly-held biopharmaceutical
company focused on allosteric modulators for neurological
disorders. From 2009 to May 2015, Mr.
Nunn served on the board of directors of Hyperion Therapeutics,
Inc. and from 2008 to February 2016,
Mr. Nunn served on the board of directors of TriVascular
Technologies, Inc. Mr. Nunn received his A.B. in economics from
Dartmouth College and his M.B.A. from
the Stanford Graduate School of Business. He also holds the
Chartered Financial Analyst designation and is a member of the CFA
Society of San Francisco.
Dr. Simeonidis is a Partner at Sarissa Capital. Prior to joining
the investment team at Sarissa Capital in 2017, he was a Managing
Director and Senior Biotechnology Analyst at the Royal Bank of
Canada (RBC) in New York since 2014. Dr. Simeonidis
spent more than a decade covering the biotechnology sector as an
analyst at a number of investment banks, including Cowen and
Company, First Albany Capital and Morgan Stanley. In addition to
his investment management and financial expertise, Dr. Simeonidis
combines both biopharmaceutical industry and biomedical research
expertise, having worked at Novartis in Business Development and
Strategic Planning, and prior to his corporate career, having
served as a faculty member at Harvard Medical School. Dr.
Simeonidis received his BS in Biology from Loyola University Chicago, and his MA, MPhil and
PhD degrees in Cellular, Molecular and Biophysical Sciences from
Columbia University's College of
Physicians & Surgeons. He completed his Postdoctoral Fellowship
at the laboratory of Professor Tucker
Collins at Harvard Medical
School and the Brigham and Women's Hospital, where he worked
on the transcriptional regulation of gene expression. Dr.
Simeonidis also holds an MBA in Healthcare Management from the
Wharton School of the University of
Pennsylvania.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus maintains its
corporate headquarters in La
Jolla, CA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-announces-new-additions-to-board-of-directors-300864996.html
SOURCE Regulus Therapeutics Inc.